Earlybird, a venture capital investor, and Andera Partners, an asset management firm, led a $103m funding round in ImCheck Therapeutics, a biotechnology company, with participation from Kurma Partners, Eurazeo, Gimv, EQT Life Sciences, Boehringer Ingelheim Venture Fund, Pfizer Ventures, Bpifrance, Wellington Partners, Agent Capital, Pureos Bioventures and Alexandria Venture Investments. “Immune checkpoint inhibitors have heralded a new era in cancer treatments and ImCheck Therapeutics is pioneering the next generation of these immunotherapeutics. In watching their progress to date, we have seen the leadership team execute on a compelling vision for a butyrophilin-based therapeutic approach from the early development stage into a highly valuable clinical development program. We at Andera Partners are confident the company will move its groundbreaking technology forward to meet patients’ needs in a range of cancer indications with wider potential for auto-immune and infectious diseases,” Raphaël Wisniewski, Andera Partners Partner.